CHMP rec­om­mends re­ject­ing Amy­lyx ALS drug, pit­ting EMA against FDA and Health Cana­da

The Eu­ro­pean Med­i­cines Agency rec­om­mend­ed that Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug be re­ject­ed with­in the EU.

The drug, known as Re­lyvrio in the US and Al­bri­oza …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER